Editorial, FranceFrance

Biotechnology for sustainable growth

20.09.2009

The present crisis marks a major breaking point in the growth model and the financial fundamentals upon which mature economies are based. It has raised important issues concerning value creation, innovation and – above all – the sustainability of European national economies. Is our growth and development model nothing more than a mirage? Will we be able to achieve sustainable growth someday? How can we build strong competitive advantages, while at the same time dealing with demographic and environmental pressures?



Biotechnology represents the largest reservoir of scientific business innovation for the French economy, as well as for Europe’s economy as a whole. Our industry now has a unique opportunity to play a key role in the definition of new, post-crisis economic and social paradigms. Ultimately, biotech is a source of sustainable, responsible growth. First of all because sustainability is an inherent part of our sector’s growth models; many discoveries still lie ahead. These new discoveries are the key link in the chain of competitive advantages European economies must grab on the global level. Secondly, our companies are working towards socially responsible and environmentally friendly economic growth. Bio­logy is “sustainable growth” by definition, as it is recyclable and not based on commodities and imports. It delivers genuine solutions for human well-being and progress in a context marked by the growth of the global population, and provides solutions for major challenges in both energy sources and use.
France Biotech is pursuing three objectives in its contributions to the development of bio­technology. The French state’s strategic investment fund (FSI) and France Biotech have just entered into an agreement aimed at creating a lead investor for breakthrough technologies, putting tens of millions of euros into three or four cutting-edge projects that can be turned into strategic technology and business advantages. This is also a possible model for a European initiative.
The second target is France’s National Research Agency (ANR), which needs to double its present budget if it is to match proportionally the scope of the NIH. We have very good researchers and we need solid, validated innovations. When a research group succeeds in identifying a new “seam”, we need to give them enough resources to fully exploit it, and recruit additional research staff by offering excellent facilities and internationally competitive salaries.
The third key objective is to maintain the “Young Innovative Company” (YIC) fiscal status, which must stay focused on true innovation. “Innovation” must remain the preserve of breakthroughs capable of generating a commercial monopoly.
Modern biotechnology is a very young field that needs time to mature. Results can take many years to achieve. At other critical junctures, France and Europe were smart enough to set early priorities in trains, aerospace and nuclear energy – so why not in the life sciences as well?

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/biotechnology-for-sustainable-growth.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON3.13 EUR5.03%
  • 4SC1.06 EUR3.92%
  • SANTHERA88.65 CHF2.78%

FLOP

  • CYTOS0.19 CHF-9.52%
  • WILEX2.13 EUR-6.99%
  • FORMYCON8.03 EUR-5.42%

TOP

  • PAION3.18 EUR30.9%
  • CO.DON3.13 EUR26.2%
  • FORMYCON8.03 EUR17.7%

FLOP

  • CYTOS0.19 CHF-24.0%
  • ADDEX3.13 CHF-21.4%
  • EVOTEC3.06 EUR-18.2%

TOP

  • SANTHERA88.65 CHF2088.9%
  • PAION3.18 EUR238.3%
  • CO.DON3.13 EUR229.5%

FLOP

  • CYTOS0.19 CHF-95.1%
  • 4SC1.06 EUR-45.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 29.09.2014


Current issue

All issues

Product of the week

Products